Bevacizumab, an anti-VEGF antibody that targets tumor angiogenesis, was granted “accelerated” approval by the FDA in 2008 after results of the E2100 randomized phase 3 trial for the first-line treatment of human epidermal receptor 2 (HER2)-negative metastatic breast cancer. The gene discussed is VEGFA; the disease is neoplasm.